How Sequestration Will Affect the Health-Care Sector and Your Pocketbook: Gilead Sciences, Inc. (GILD), Life Technologies Corp. (LIFE)

Page 1 of 2

Stop me if you’ve heard this joke before: “Two political parties walk into a bar; both point the finger at each other for the country’s fiscal mess, yet neither is willing to budge an inch from their underlying views…” My guess is you’ve heard this one all too often and it’s not even funny anymore… because the truth rarely is.

Gilead Sciences, Inc. (NASDAQ:GILD)The highly anticipated sequestration, aimed at removing $1.1 trillion out of the federal budget over the next decade, kicked into effect on March 1, and is set to gradually, but decisively, remove $85 billion from the federal budget. These cuts are going to come from all walks of government – from USDA inspectors, to military spending, and even entitlement programs like Medicare, which is expected to see approximately a 2% reduction in reimbursements.

Today, I want to take a closer look at how sequestration could impact the health care sector.

As you might imagine, many of the effects of removing government funding tend to be negative — but it’s not as cut-and-dried as it might appear on the surface.

How it’ll affect safety
The most immediate impact of sequestration appears to be whether patient and consumer safety will be affected negatively. On the surface I’d say this is a distinct possibility with the Centers for Disease Control and Prevention seeing nearly a $450 million cut in its budget and the FDA, whose expenses are predominantly tied to its personnel costs, alluding that a $318 million reduction in funds will result in layoffs or furloughs totaling 2,100 USDA food inspectors.

Food safety looks like a clear loser with Tyson Foods, Inc. (NYSE:TSN) and Smithfield Foods, Inc. (NYSE:SFD) projected to suffer from USDA furloughs. By law, processed meat cannot be sold in stores without having been inspected, leaving Tyson and Smithfield in a big bind come the summer time when these furloughs are expected to hit the hardest. The end result may be less meat on supermarket shelves and higher prices because of it.

The bigger concern here actually stems from the CDC’s reduced budget. As GlobalData analysts noted this past week, one of the CDC’s primary functions is to provide educational and preventative materials and products to curb the spread of infectious diseases such as hepatitis and HIV. A lack of funding here could result in higher occurrences of these infectious diseases. However, I disagree with their analysis that this negative occurrence could have the hidden benefit of driving down costs as providers opt for cheaper drugs in the HIV space, hurting the launch of expensive new offerings like. Gilead Sciences, Inc. (NASDAQ:GILD)‘s four-in-one HIV medication, Stribild. Made with all in-house compounds, if Stribild supplants Gilead Sciences, Inc. (NASDAQ:GILD)’s current best-selling HIV treatment, Atripla, it will result in higher margins for the company. Keeping things in perspective, I wouldn’t expect a huge spike in HIV occurrences, but I wouldn’t be surprised if documented cases rose year-over-year.

How it’ll affect research and development
Research and development in pharmaceuticals, biotech, and life sciences looks like it’ll be a bit of a mixed bag. The National Institutes of Health is expected to be dealt a big blow with a reduction in funding of more than $1.6 billion. That means somewhere in the neighborhood of 2,000 fewer grants will be issued. In addition, a reduction in FDA budgets, while being dealt with largely on the food inspection front, could translate to slower drug and device approval. That would be bad news for potential drugs that aren’t set to be examined by the FDA until the latter half of 2013, including GlaxoSmithKline plc (ADR) (NYSE:GSK) and Theravance Inc (NASDAQ:THRX)‘s revolutionary long-term COPD treatment, Anoro, which I declared as a game-changing drug hopeful late last year.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!